Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer

Alberto Ravaioli, Maurizio Marangolo, Enzo Pasquini, Andrea Rossi, Dino Amadori, Giorgio Cruciani, Davide Tassinari, Giovanni Oliverio, Petros Giovanis, Daniele Turci, Federica Zumaglini, Mario Nicolini, Ilaria Panzini

Research output: Contribution to journalArticlepeer-review


Purpose: A phase II trial investigated the activity and toxicity of a bolus administration schedule of oxaliplatin, fluorouracil (5-FU), and leucovorin (LV) therapy in patients with untreated advanced colorectal cancer. Patients and Methods: Forty-five patients in this multicenter, open, nonrandomized study received oxaliplatin 130 mg/m2 on the first day of each course and 5-FU and LV 350 mg/m2 and 20 mg/m2, respectively, as a daily bolus for 5 days, every 21 days, for a maximum of six courses. Results: Partial responses occurred in 18 patients, giving an intent-to-treat response rate of 40.0%. Median time to response was 12.7 weeks; median duration of response was 18.4 weeks. Median progression-free survival was 5.9 months; median survival was 14 months. The independent prognostic factors for improved overall survival were good performance status and negative carcino-embryonic antigen blood level. Incidences of adverse effects were reduced after the 5-FU dose was reduced to 300 mg/m2. Reversible neurologic toxicity occurred in 44.4% of patients. Conclusion: Bolus administration of oxaliplatin, 5-FU, and LV as first-line therapy for untreated advanced colorectal cancer is efficacious and safe. In addition to a more favorable safety profile, the 300 mg/m2 dosage offered improved dose-intensity compared with the initial dosage.

Original languageEnglish
Pages (from-to)2545-2550
Number of pages6
JournalJournal of Clinical Oncology
Issue number10
Publication statusPublished - May 15 2002

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this